Streetbeat News

Stock Prices

ASND

Ascendis Pharma's shares rose following the announcement of positive topline data from its pivotal trial of Transcon CNP (Navepegritide).

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 1:17 pm

ETHUSD

An Ether (ETH) investor turned an $87,006 investment into $38 million over eight years, highlighting the potential of long-term holding strategies in the volatile crypto market. Despite selling some ETH for significant gains, the investor still holds a substantial amount. The story contrasts with other trading strategies, including a failed Bitcoin bet by James Fickel, which resulted in significant debt.

Portfolio Pulse from Murtuza Merchant

September 16, 2024 | 1:16 pm

AAPL

AI

INTC

NVDA

QQQ

TSLA

The article lists the top 10 trending stocks on WallStreetBets as of September 16, 2024, according to Swaggy Stocks. The stocks mentioned include NVDA, AAPL, INTC, WAY, MADE, LOT, DJT, TSLA, AI, and QQQ.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 1:14 pm

ILAG

Intelligent Living Application Group has regained compliance with Nasdaq's listing requirements, ensuring its continued presence on the exchange.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 1:10 pm

IPA

ImmunoPrecise Antibodies (NASDAQ:IPA) reported a Q1 2025 GAAP EPS of $(0.15), missing the $(0.13) estimate. Sales were $5.3M, below the $6.75M estimate, but up 24.35% from last year.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 1:02 pm

CMS

CMS Energy (NYSE:CMS) has been analyzed by 8 analysts, showing a range of sentiments from bullish to bearish. Recent analyst actions include several rating upgrades and increased price targets, with an average 12-month price target of $68.0. CMS Energy has shown strong financial performance with notable revenue growth, high net margin, and efficient asset management, though it carries a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

September 16, 2024 | 1:01 pm

ENLC

EnLink Midstream (NYSE:ENLC) has been analyzed by 8 analysts, showing a range of perspectives from bullish to bearish. The average 12-month price target has increased by 5.11% to $15.62. Analysts have maintained or adjusted their ratings, reflecting dynamic market conditions. Despite revenue growth, EnLink faces challenges with net margin, ROE, ROA, and debt management.

Portfolio Pulse from Benzinga Insights

September 16, 2024 | 1:01 pm

AGYS

In the past three months, 5 analysts have reviewed Agilysys (NASDAQ:AGYS), with most ratings being bullish. The average 12-month price target has increased by 11.45% to $122.6. Agilysys shows strong financial performance with high net margins and ROE, despite trailing in revenue growth compared to peers.

Portfolio Pulse from Benzinga Insights

September 16, 2024 | 1:01 pm

SWIM

Latham Group (NASDAQ:SWIM) has received mixed analyst ratings, with a recent average price target increase to $5.66. Analysts have raised their ratings, reflecting positive sentiment despite a recent revenue decline. The company's financial metrics show strong net margin and ROE, but high debt levels.

Portfolio Pulse from Benzinga Insights

September 16, 2024 | 1:00 pm

ZNTL

The FDA has lifted the partial clinical hold on Zentalis Pharmaceuticals' azenosertib studies, allowing the company to resume enrollment in all ongoing clinical trials. This decision follows a comprehensive safety assessment after two deaths in a previous study. Zentalis plans to present further data later this year and remains on track with its 2024 data guidance.

Portfolio Pulse from Vandana Singh

September 16, 2024 | 1:00 pm